Categories: Health

Declaration of shares and voting rights of Valneva SE March 2026

VALNEVA

Declaration of shares and voting rights
March 31, 2026
__________________________________________________________________________________________

Company name: VALNEVA
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon
Regulated market of Euronext Paris – Compartment B

Declaration date: April 3, 2026

Number of shares
composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 

173,877,420

ordinary shares with a par value of €0.15 each

188,465,862 Transfer into bearer form of 521,353 shares with double voting rights

Double voting rights granted on 119,111 ordinary shares

Between March 3 & March 23, 2026

Between March 5 & March 22, 2026

188,341,540

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
** Net (or exercisable at a General Meeting) voting rights.

GlobeNews Wire

Recent Posts

Brandwatch Expands APAC Data Coverage to Strengthen Global Insight for Marketers

New access to key APAC platforms helps global enterprises understand fragmented global audiences and act with greater…

39 minutes ago

Inside the World of UCEED Rankers Experiencing Design in Action

AHMEDABAD, India, April 22, 2026 /PRNewswire/ -- For most of India's brightest design aspirants, clearing UCEED…

39 minutes ago

/C O R R E C T I O N — Smashify/

In the news release, SMASHIFY LAUNCHES BETA PLATFORM TO REWRITE THE STREAMING EXPERIENCE FOR ARTIST…

39 minutes ago

First-quarter 2026 revenue

Revenue as at 31 March 2026 stood at €1,336m, up +4.9% on an organic basis…

3 hours ago

IMAAVY (nipocalimab)shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG…

3 hours ago

Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting

April 23, 2026 12:00 ET  | Source: Catheter Precision, Inc. VIVO System to be featured…

3 hours ago